Compare KB Financial Group, Inc. (KB) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs Sana Biotechnology Inc — how do they compare? KB Financial Group, Inc. trades at $123.07 (market cap $42.62B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: KB Financial Group, Inc. is far larger — about 50.9× Sana Biotechnology Inc's market cap, and KB Financial Group, Inc. pays a 2.71% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold KB Financial Group, Inc. for 33 Days and Sana Biotechnology Inc for 23 Days on average.
| KB | SANA | |
|---|---|---|
Market Cap | $42.62B | $836.71M |
Volume | 164,291 | 4,507,444 |
Sector | Financials | Health |
52-Week High | $132.88 | $5.92 |
52-Week Low | $77.50 | $2.68 |
Typical Hold Time | 33 Days | 23 Days |
Enterprise Value | $215.53T | $749.96M |
Dividend Yield | 2.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KB Financial Group (KB) trades at $122.04, down 2.16% on the day, with mixed technical signals showing a neutral overall trend. The company demonstrates strong fundamental performance with consistent earnings beats, revenue growth from $21.23T in 2025 to projected $22.37T in 2026, and attractive valuation metrics including a P/E of 9.68 and P/B of 0.94. Recent analyst coverage shows 33% buy ratings with positive momentum highlighted in multiple financial publications.
The outlook remains positive given KB's consistent earnings outperformance and improving profitability margins. Key opportunities include the stock's valuation discount to peers and South Korea's strong market performance. Risks include market volatility and the company's high interest expense of $16.08T. The combination of fundamental strength and reasonable valuation supports a constructive view for long-term investors.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
